JP2017537622A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537622A5 JP2017537622A5 JP2017529284A JP2017529284A JP2017537622A5 JP 2017537622 A5 JP2017537622 A5 JP 2017537622A5 JP 2017529284 A JP2017529284 A JP 2017529284A JP 2017529284 A JP2017529284 A JP 2017529284A JP 2017537622 A5 JP2017537622 A5 JP 2017537622A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- seq
- acid sequence
- domain
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000007523 nucleic acids Chemical group 0.000 claims 51
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 34
- 108020004707 nucleic acids Proteins 0.000 claims 16
- 102000039446 nucleic acids Human genes 0.000 claims 16
- 210000004027 cell Anatomy 0.000 claims 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims 11
- 239000013598 vector Substances 0.000 claims 10
- 102100025825 Methylated-DNA-protein-cysteine methyltransferase Human genes 0.000 claims 9
- 108040008770 methylated-DNA-[protein]-cysteine S-methyltransferase activity proteins Proteins 0.000 claims 9
- 230000011664 signaling Effects 0.000 claims 9
- 102000003816 Interleukin-13 Human genes 0.000 claims 8
- 108090000176 Interleukin-13 Proteins 0.000 claims 8
- 210000004962 mammalian cell Anatomy 0.000 claims 6
- 229920001184 polypeptide Polymers 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 6
- 230000001086 cytosolic effect Effects 0.000 claims 5
- 239000003446 ligand Substances 0.000 claims 5
- 239000013603 viral vector Substances 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 229940127089 cytotoxic agent Drugs 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims 3
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 2
- 230000000139 costimulatory effect Effects 0.000 claims 2
- 230000001177 retroviral effect Effects 0.000 claims 2
- 108010016626 Dipeptides Proteins 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 208000029824 high grade glioma Diseases 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 201000011614 malignant glioma Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108010091748 peptide A Proteins 0.000 claims 1
- 102200146131 rs1131692037 Human genes 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462086346P | 2014-12-02 | 2014-12-02 | |
| US62/086,346 | 2014-12-02 | ||
| PCT/US2015/063267 WO2016089916A1 (en) | 2014-12-02 | 2015-12-01 | Methods and compositons for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017537622A JP2017537622A (ja) | 2017-12-21 |
| JP2017537622A5 true JP2017537622A5 (cg-RX-API-DMAC7.html) | 2019-01-10 |
Family
ID=56078487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017529284A Pending JP2017537622A (ja) | 2014-12-02 | 2015-12-01 | がんを治療するための方法及び組成物 |
Country Status (18)
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9512194B2 (en) | 2012-01-27 | 2016-12-06 | The Board Of Trustees Of The Leland Stanford Junior University | Modified IL-13 polypeptides |
| IN2015KN00329A (cg-RX-API-DMAC7.html) | 2012-08-09 | 2015-07-10 | Univ Leland Stanford Junior | |
| ES2776698T3 (es) | 2012-12-20 | 2020-07-31 | Purdue Research Foundation | Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer |
| US10106592B2 (en) | 2013-09-24 | 2018-10-23 | Medicenna Therapeutics Inc. | Interleukin-4 receptor-binding fusion proteins and uses thereof |
| SG11201704519YA (en) | 2014-12-02 | 2017-07-28 | Roger Williams Hospital | Methods and compositons for treating cancer |
| EP3310805B1 (en) * | 2015-06-19 | 2021-02-17 | Kobold, Sebastian | Pd-1-cd28 fusion proteins and their use in medicine |
| US10975148B2 (en) * | 2015-08-05 | 2021-04-13 | CellabMED Inc. | Chimeric antigen receptors, and T cells in which chimeric antigen receptor is expressed |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Car t細胞療法のための方法および組成物 |
| US20200095301A1 (en) * | 2016-12-14 | 2020-03-26 | The Board Of Trustees Of The Leland Stanford Junior University | Il-13 superkine: immune cell targeting constructs and methods of use thereof |
| US11649288B2 (en) | 2017-02-07 | 2023-05-16 | Seattle Children's Hospital | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents |
| WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
| AU2018256436B2 (en) | 2017-04-19 | 2024-12-05 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
| WO2019073299A1 (en) | 2017-10-10 | 2019-04-18 | Medicenna Therapeutics, Inc. | IL-4 FUSION FORMULATIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) TUMORS |
| MX2020005251A (es) * | 2017-11-20 | 2021-01-29 | Prospect Chartercare Rwmc Llc D/B/A Roger Williams Medical Center | Composiciones para mejorar la funcionalidad de células car-t y uso de las mismas. |
| KR20250010750A (ko) * | 2017-12-20 | 2025-01-21 | 포세이다 테라퓨틱스, 인크. | Vcar 조성물 및 사용 방법 |
| CN112292138A (zh) | 2018-01-22 | 2021-01-29 | 西雅图儿童医院(Dba西雅图儿童研究所) | Car t细胞的使用方法 |
| EP3743445A1 (en) * | 2018-01-26 | 2020-12-02 | City of Hope | Chimeric antigen receptors and methods for reducing off target toxicity |
| SG11202007426XA (en) | 2018-02-06 | 2020-09-29 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors |
| CN110144326A (zh) * | 2018-02-12 | 2019-08-20 | 深圳宾德生物技术有限公司 | 一种靶向性抗肿瘤t细胞及其制备方法和应用 |
| CN110157674A (zh) * | 2018-02-12 | 2019-08-23 | 深圳宾德生物技术有限公司 | 一种靶向性t淋巴细胞及其制备方法和应用 |
| EP3755349A4 (en) | 2018-02-21 | 2021-11-17 | Board of Regents, The University of Texas System | PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES |
| WO2019165237A1 (en) | 2018-02-23 | 2019-08-29 | Endocyte, Inc. | Sequencing method for car t cell therapy |
| CN108440674A (zh) * | 2018-04-28 | 2018-08-24 | 杭州荣泽生物科技有限公司 | 一种Trop-2特异性嵌合抗原受体细胞制备及其用途 |
| WO2019239213A2 (en) | 2018-06-01 | 2019-12-19 | Medicenna Therapeutics Inc. | Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof |
| EP4097127A2 (en) * | 2020-01-31 | 2022-12-07 | City of Hope | TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS FOR TREATMENT OF IL13Ralpha2 POSITIVE MALIGNANCIES |
| US20230203108A1 (en) * | 2020-05-28 | 2023-06-29 | Chugai Seiyaku Kabushiki Kaisha | Improved granzyme b variant |
| US20230364139A1 (en) * | 2020-08-26 | 2023-11-16 | The Regents Of The University Of California | Methods and compositions for treating glioblastoma |
| WO2022056398A1 (en) * | 2020-09-11 | 2022-03-17 | University Of Georgia Research Foundation, Inc. | Compositions and methods of use thereof for prevention and treatment of influenza infections |
| JP2024500847A (ja) | 2020-12-18 | 2024-01-10 | センチュリー セラピューティクス,インコーポレイテッド | 適合可能な受容体特異性を有するキメラ抗原受容体システム |
| CN118146395A (zh) * | 2021-02-08 | 2024-06-07 | 浙江大学 | 一种以内源性蛋白质分子替代单结构域抗体的嵌合抗原受体 |
| CN113304267B (zh) * | 2021-06-11 | 2022-03-15 | 河南大学 | 肺癌的治疗靶点及其应用 |
| CN114014941B (zh) * | 2022-01-10 | 2022-04-12 | 卡瑞济(北京)生命科技有限公司 | 靶向IL13Rα2的嵌合抗原受体及其用途 |
| CN116549667B (zh) * | 2023-05-29 | 2024-02-09 | 四川普锐特药业有限公司 | 一种pas修饰的脂质纳米粒、包含其的药物制剂,及其制备方法和用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5965126A (en) * | 1996-03-25 | 1999-10-12 | The Penn State Research Foundation | use of mutant alkyltransferases for gene therapy to protect from toxicity of therapeutic alkylating agents |
| EP1222289B1 (en) * | 1999-10-20 | 2008-04-16 | The Johns Hopkins University School Of Medicine | Chimeric immunogenic compositions and nucleic acids encoding them |
| US20030235555A1 (en) * | 2002-04-05 | 2003-12-25 | David Shealey | Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses |
| JP2005518800A (ja) * | 2002-03-01 | 2005-06-30 | ブリストル−マイヤーズ スクイブ カンパニー | 構成的に活性化されたチロシンキナーゼレセプターを発現するトランスジェニック非ヒト哺乳動物 |
| US7709625B2 (en) * | 2004-06-10 | 2010-05-04 | The Board Of Regents Of The University Of Texas | Methods and compositions for bone marrow stem cell-derived macrophage delivery of genes for gene therapy |
| AU2005339587B2 (en) * | 2005-11-16 | 2011-11-03 | Universidad Nacional Autonoma De Mexico | Use of transcriptome-modifying agents and chemotherapy or radiotherapy against cancer |
| CN101438158A (zh) * | 2006-03-06 | 2009-05-20 | 阿穆尼克斯股份有限公司 | 遗传包和其应用 |
| US20080206139A1 (en) * | 2006-11-03 | 2008-08-28 | The Penn State Research Foundation | Delivery system for diagnostic and therapeutic agents |
| JP2012501180A (ja) * | 2008-08-26 | 2012-01-19 | シティ・オブ・ホープ | T細胞の抗腫瘍エフェクター機能増進のための方法および組成物 |
| US9273283B2 (en) * | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
| EP3222632A1 (en) * | 2010-03-26 | 2017-09-27 | Memorial Sloan-Kettering Cancer Center | Antibodies to muc16 and methods of use thereof |
| WO2014090985A1 (en) * | 2012-12-13 | 2014-06-19 | Universität Leipzig | T-cell modulation by exon skipping |
| PL3300745T3 (pl) * | 2013-02-15 | 2020-03-31 | The Regents Of The University Of California | Chimeryczny receptor antygenowy i sposoby jego zastosowania |
| HK1220614A1 (zh) * | 2013-03-10 | 2017-05-12 | Baylor College Of Medicine | 耐化疗免疫细胞 |
| EP3105333B1 (en) * | 2014-02-10 | 2020-04-08 | Emory University | Expression of chimeric polypeptide with variable lymphocyte receptors on immune cells and uses for treating cancer |
| SG11201704519YA (en) | 2014-12-02 | 2017-07-28 | Roger Williams Hospital | Methods and compositons for treating cancer |
-
2015
- 2015-12-01 SG SG11201704519YA patent/SG11201704519YA/en unknown
- 2015-12-01 MX MX2017007272A patent/MX2017007272A/es unknown
- 2015-12-01 HK HK18110565.4A patent/HK1251862A1/zh unknown
- 2015-12-01 SG SG10202103475XA patent/SG10202103475XA/en unknown
- 2015-12-01 CA CA2969714A patent/CA2969714A1/en not_active Abandoned
- 2015-12-01 AU AU2015355084A patent/AU2015355084A1/en not_active Abandoned
- 2015-12-01 JP JP2017529284A patent/JP2017537622A/ja active Pending
- 2015-12-01 CN CN201580074883.3A patent/CN107709353A/zh active Pending
- 2015-12-01 BR BR112017011771A patent/BR112017011771A2/pt not_active Application Discontinuation
- 2015-12-01 US US14/956,299 patent/US9650428B2/en not_active Expired - Fee Related
- 2015-12-01 EA EA201791210A patent/EA201791210A1/ru unknown
- 2015-12-01 KR KR1020177018139A patent/KR20180041087A/ko not_active Withdrawn
- 2015-12-01 WO PCT/US2015/063267 patent/WO2016089916A1/en not_active Ceased
- 2015-12-01 EP EP15865800.5A patent/EP3227317A4/en not_active Withdrawn
- 2015-12-02 UY UY0001036418A patent/UY36418A/es not_active Application Discontinuation
- 2015-12-02 TW TW104140317A patent/TW201636425A/zh unknown
- 2015-12-02 AR ARP150103939A patent/AR102879A1/es unknown
-
2017
- 2017-05-09 US US15/590,961 patent/US20180072789A1/en not_active Abandoned
- 2017-06-01 IL IL252610A patent/IL252610A0/en unknown
- 2017-06-02 PH PH12017501031A patent/PH12017501031A1/en unknown